Compare ESRT & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESRT | OABI |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 799.9M | 773.1M |
| IPO Year | 2012 | 2021 |
| Metric | ESRT | OABI |
|---|---|---|
| Price | $5.20 | $5.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $5.30 | ★ $8.33 |
| AVG Volume (30 Days) | ★ 4.1M | 1.4M |
| Earning Date | 11-02-2026 | 10-30-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $768,270,000.00 | $18,666,000.00 |
| Revenue This Year | N/A | $94.10 |
| Revenue Next Year | N/A | $30.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.05 | N/A |
| 52 Week Low | $3.93 | $1.35 |
| 52 Week High | $7.48 | $5.45 |
| Indicator | ESRT | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 64.59 | 53.60 |
| Support Level | $4.87 | $4.43 |
| Resistance Level | $5.85 | $5.30 |
| Average True Range (ATR) | 0.16 | 0.39 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 73.97 | 63.18 |
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.